Hospital Quironsalud Malaga
- Address
- lock Available on a paid plan
Oncology Research
The department focuses on non‑small cell lung cancer, breast cancer, melanoma and other solid tumors, aiming to test new targeted agents, immunotherapy combinations and antibody‑drug conjugates to improve survival and disease control.
- Immunotherapy‑based combination trials
- Antibody‑drug conjugate efficacy studies
- Targeted therapy for EGFR‑mutated lung cancer
- Adjuvant treatments after surgical resection
With 62 active trials and 33 investigators, Hospital Quironsalud Malaga is a leading hub for innovative cancer research in southern Europe.
Cardiovascular & Metabolic Studies
Trials address acute myocardial infarction, atherosclerotic cardiovascular disease, severe hypertriglyceridemia, obesity and overweight, exploring lipid‑lowering agents, cardioprotective drugs and weight‑management strategies to reduce cardiovascular risk.
- Novel triglyceride‑lowering therapies
- Cardiovascular outcome trials in ASCVD
- Weight‑loss interventions for obesity‑related heart disease
- Early‑intervention strategies after myocardial infarction
The site integrates endocrinology and nutrition expertise to evaluate metabolic health alongside heart disease.
Neurology & Psychiatry
Research includes patients with Alzheimer's dementia‑related agitation, psychosis, and schizophrenia, testing novel antipsychotics, symptom‑targeted agents and cognitive‑support therapies to enhance patient well‑being.
- Anti‑agitation compounds for dementia
- Negative‑symptom treatments in schizophrenia
- Long‑term safety of psychosis‑targeted drugs
- Combination approaches with standard care
These studies aim to provide safer, more effective options for neuropsychiatric conditions.
Respiratory & Allergy Research
The site evaluates therapies for chronic cough, allergic rhinitis, asthma and related airway disorders, focusing on novel cough modulators, allergen immunotherapy and anti‑inflammatory agents to improve respiratory function.
- Cough‑frequency reduction trials
- Allergen‑specific immunotherapy for house‑dust‑mite allergy
- Biologic treatments for severe asthma
- Patient‑reported outcome measures in respiratory disease
Collaborative efforts with pulmonology enhance the breadth of respiratory investigations.
Infectious Disease & Immunology
Studies target cytomegalovirus, meningococcal infection, bacterial and fungal diseases, and vaccine safety, evaluating antiviral agents, novel antibiotics and immunogenicity of next‑generation vaccines.
- Antiviral efficacy in CMV prevention
- Safety and reactogenicity of multivalent meningococcal vaccines
- New antimicrobial regimens for resistant infections
- Immune response profiling in vaccine trials
These trials support public health goals by advancing therapeutic and preventive options.
Musculoskeletal & Bone Health
Research includes participants with knee osteoarthritis, overweight, and related joint disorders, testing weight‑loss drugs, pain‑relief agents and disease‑modifying therapies to improve mobility and quality of life.
- Weight‑reduction compounds for obese OA patients
- Analgesic efficacy of novel topical agents
- Structural outcomes in osteoarthritis progression
- Integrated lifestyle and pharmacologic interventions
The multidisciplinary approach combines endocrinology, nutrition and orthopedics to address musculoskeletal health.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 19 therapeutic areas and 15 of 157 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 134 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 35 by active trials.
- 1Merck Sharp & Dohme LLC4active
lock +34 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC4trials
lock +13 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Quironsalud Malaga
lock Showing 1 of 76 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Comparative Study of ABP 234 and Pembrolizumab in Patients with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Amgen Inc. | Phase I | Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 157 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 14 | Unknown | 2021-07-28 | 2026-07-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.